Clinical Trials
41 trialsSEVILLA
UNICANCER
HAIC Plus Systemic Therapy as De-escalation Therapy Strategy for Biliary Tract Cancer
Peking University
CLEAR-04
Fudan University
CLEAR-02
Fudan University
GRACIE
UNICANCER
FUDOSE
UNICANCER
CIME
Centre Leon Berard
Phase I Trial of 5-Fluorouracil (5FU) -Based Therapy in Combination With Hydroxytyrosol (HT) in Patients With Advanced or Metastatic Colorectal Cancer
The Methodist Hospital Research Institute
MRI-Guided Adaptive Radiation Therapy for Organ Preservation in Rectal Cancer
Medical College of Wisconsin
Response Adapted Neoadjuvant Therapy in Gastroesophageal Cancers (RANT-GC Trial)
University of California, Irvine
FOBEAR
Sun Yat-sen University
Pilot Study of an Implantable Microdevice for In Situ Evaluation of Drug Response in Patients With Colorectal Liver Metastasis
Northwell Health
CAPRI-3 GOIM
University of Campania Luigi Vanvitelli
NALIRIFOX Plus Targeted Therapy Versus FOLFOX Plus Targeted Therapy as First-line Treatment for Metastatic Colorectal Cancer
Shanghai Zhongshan Hospital
Immune Checkpoint Inhibitors + Chemotherapy Versus Chemotherapy in the Neoadjuvant Treatment of Locally Advanced Colorectal Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Folfox+Irinotecan+Chemort In Esophageal Cancer
Massachusetts General Hospital
The Phase 1b/IIa, Open-label, Dose Escalation and Dose Expansion to Evaluate Safety, Tolerability, and Preliminary Efficacy of the Combination of HCB101, Cetuximab/Bevacizumab, and FOLFOX/FOLFIRI in Advanced or Metastatic Colorectal Cancer
Chang Gung Memorial Hospital
Systemic Chemotherapy With FOLFOX Plus Atezolizumab & Bevacizumab for Patients With Advanced HCC Who Previously Received Atezolizumab & Bevacizumab
Sun Yat-sen University
BIG
GERCOR - Multidisciplinary Oncology Cooperative Group
PANTHER
Weill Medical College of Cornell University
A Clinical Trial to Evaluate the Safety, Tolerability and Clinical Efficacy of M3T01 Monotherapy and in Combination With Pembrolizumab and Other Systemic Therapies
Providence Health & Services
ICT-HCC
Nanjing Tianyinshan Hospital
Hypo-OPRA
McGill University Health Centre/Research Institute of the McGill University Health Centre
COSENSE-1
St. Olavs Hospital
FOxTROT2France
Centre Hospitalier Universitaire Dijon
PIPAC_VEROne
Azienda Ospedaliera Universitaria Integrata Verona
ARO 2024-13
University Hospital Tuebingen
REPROGRAM-02
Centre Hospitalier Universitaire de Besancon
CLAUDIA
Seoul National University Hospital
Combination of IV Ascorbic Acid and Adebrelimab in Metastatic Colorectal Cancer
Fudan University
LOGICAN
UNICANCER
PRAAR1
Gustave Roussy, Cancer Campus, Grand Paris
Cadonilimab in Combination With Bevacizumab and FOLFOX Regimen for the First-Line Treatment of Advanced Unresectable MSS-Type, RAS-Mutated Metastatic Colorectal Cancer
Fudan University
ctDNA-guided Adjuvant Chemotherapy in Liver Metastasis of Colorectal Cancer
Sixth Affiliated Hospital, Sun Yat-sen University
Postoperation Maintenance Therapy for Resectable Liver Metastases of Colorectal Cancer Guided by ctDNA
Sixth Affiliated Hospital, Sun Yat-sen University
A Study of the Application of HAIC in Advanced HCC Previously Treated With ICIs and Antiangiogenic Agents
Sun Yat-sen University
HAIC With One-day FOLFOX vs. HAIC With Two-day FOLFOX for Unresectable HCC: a Non-inferiority Study
Sun Yat-sen University
PelvEx II
Catharina Ziekenhuis Eindhoven
Neoadjuvant FOLFOXIRI Versus Immediate Surgery for Stage II and III Colon Cancers
Sun Yat-sen University
JSFOL
Xiangya Hospital of Central South University
Mebendazole as Adjuvant Treatment for Colon Cancer
Tanta University